Combination Therapy Shows Superior Event-Free Survival for Acute Myeloid Leukemia in Phase 2 Trial

A Phase 2 randomized trial published in The New England Journal of Medicine indicates that azacitidine-venetoclax therapy significantly extended event-free survival compared to standard induction chemotherapy in adults with newly diagnosed acute myeloid leukemia (AML) who were eligible for intensive chemotherapy. Patients receiving the combination experienced 14.5 months before treatment failure, leukemia recurrence, worsening, or death, versus 6.2 months for those on intensive chemotherapy.